platinum has been researched along with aprepitant in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Gaillard, R; Giroux, J; Goldwasser, F; Mir, O; Ropert, S | 1 |
| He, M; Liu, M; Liu, Q; Wei, Y; Xu, R; Yi, F; Zhang, W; Zhang, Y | 1 |
1 review(s) available for platinum and aprepitant
| Article | Year |
|---|---|
Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; China; Dexamethasone; Humans; Lung Neoplasms; Morpholines; Nausea; Platinum; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Vomiting | 2021 |
1 other study(ies) available for platinum and aprepitant
| Article | Year |
|---|---|
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Aprepitant; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Platinum; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Vomiting | 2012 |